Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Thermo Fisher Scientific Further Expands Global Footprint | Contract Pharma

What are you searching for?

Sign in
Breaking News

Thermo Fisher Scientific Further Expands Global Footprint

Will expand sites in Greenville, NC; Swindon, UK; and Ferentino and Monza, Italy for sterile drug product development and commercial manufacturing.

By: Contract Pharma

Contract Pharma Staff

Thermo Fisher Scientific will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.

Thermo Fisher will expand sites in Greenville, NC; Swindon, UK; and Ferentino and Monza, Italy. The investment will add 15 development and cGMP commercial production lines, as well as a range of capabilities including live virus, aseptic liquid and lyophilized vial filling. These projects are expected to be completed over the next two years and will create approximately 1,000 jobs.

In addition, the company recently announced significant projects in Asia-Pacific, including a new sterile manufacturing facility in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.

“We have continued to invest strategically in capacity, technology and expertise across our global network so we can accelerate innovation and enhance productivity for our customers,” said Mike Shafer, senior vice president and president, pharma services, Thermo Fisher Scientific. “This has enabled us to respond quickly and support our customers with unprecedented scale and depth of capabilities to meet high demand for new therapies and vaccines. By simplifying the supply chain and solving complex manufacturing challenges, we shorten development timelines in order to get high-quality medicines to patients, faster.”

“With these investments, we’ve nearly doubled our global footprint for drug development and commercial manufacturing, which allows us to support our customers with unmatched flexibility, expertise and scale at a time of unprecedented demand,” added Shafer.

The activities underscore the rapidly growing global demand for injectable sterile drugs, which comprise 46% of the total dosage forms securing U.S. FDA approval in 2019 (vs. 25% a decade ago).
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics